Gene Logic, Abbott strike development deal

Gene Logic has inked a deal with Abbott to study new pathways for a group of experimental therapies that have passed Phase I. The deal gives Gene Logic a schedule of milestone payments for any successful new programs. Gene Logic's Drug Repositioning Program seeks to find alternative indications for drug candidates with good safety records that have been de-prioritized or discontinued in clinical trials. This is the fifth alliance with Big Pharma by Gene Logic.

- see this release on the pact

Related Articles:
Gene Logic re-examines Organon candidates. Report
Gene Logic cuts jobs at struggling genomics division. Report